Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1047 | Pituitary - Clinical | ECE2017

Considerable delays to achieve adequate control in treating patients with acromegaly

Tzanela Marinella , Karapanou Olga , Giatra Christianna , Botoula Efstathia , Tiaka Elisabeth , Anastasia Lambraki , Tsagarakis Stylianos

Acromegaly is a rare disease that leads to considerable morbidity and mortality, both reversible by adequate control of the disease. However, patients that could be adequately controlled confront delays in achieving treatment targets. The aim of the present study was to estimate the time to disease control after diagnosis and the reason leading to control delays. We retrospectively studied 119 acromegalic patients (aged 46.4±12.5; 71 females). Following appropriate treatm...

ea0032p896 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Effect of treatment outcome on co-morbidities of Cushing's disease

Assimakopoulou Athina , Tzanela Marinella , Palimeri Sotiria , Karapanou Olga , Botoula Efi , Tsagarakis Stylianos

Generously supported by IPSEN)-->Endogenous hypercortisolism leads to increased morbidity and mortality. As Cushing’s disease (CD) is a rare disorder, data on co-morbidities outcome after current treatment interventions are scarce.We studied 78 patients with CD (67 females, 11 males, mean age 42.2±1.4 years), with a follow up of 90.8±7.8 months. All patients underwent transsphenoidal surgery (TSS...

ea0099rc6.4 | Rapid Communications 6: Thyroid | Part I | ECE2024

Local treatment improves outcome of RAI - Refractory differentiated thyroid carcinoma (DTC) patients irrespectively of tyrosine kinase inhibitors (TKI) treatment: a single center experience

Karapanou Olga , Kantreva Kanella , Paschou Stavroula A. , Michalaki Marina , Alevizaki Maria , Saltiki Katerina

Purpose: Although the majority of differentiated thyroid cancer (DTC) patients have favorable outcome, approximately up to 20% of them may develop metastatic and/or locoregional disease persistence. One-third of those patients may not respond to the treatment with radioiodine (RAI refractory DTC, RAI-R DTC). There are few reports of real-life experience concerning the clinical course and the treatment modalities that have been used in patients with RAI-R DTC.<p class="abst...